811.737 USD
-0.53 (-0.07%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 530 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year REGN was profitable.
In the past year REGN had a positive cash flow from operations.
Each year in the past 5 years REGN has been profitable.
REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
REGN has a Return On Assets of 11.40%. This is amongst the best in the industry. REGN outperforms 94.34% of its industry peers.
REGN has a Return On Equity of 14.79%. This is amongst the best in the industry. REGN outperforms 94.72% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.69%, REGN belongs to the top of the industry, outperforming 94.34% of the companies in the same industry.
REGN had an Average Return On Invested Capital over the past 3 years of 12.44%. This is significantly below the industry average of 18.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN's Profit Margin of 32.13% is amongst the best of the industry. REGN outperforms 96.42% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
REGN has a better Operating Margin (27.61%) than 96.42% of its industry peers.
REGN's Operating Margin has declined in the last couple of years.
REGN has a Gross Margin of 86.28%. This is amongst the best in the industry. REGN outperforms 88.87% of its industry peers.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
REGN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, REGN has less shares outstanding
The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
REGN has an Altman-Z score of 7.86. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
REGN's Altman-Z score of 7.86 is fine compared to the rest of the industry. REGN outperforms 78.30% of its industry peers.
REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
REGN has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. REGN outperforms 94.72% of its industry peers.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
REGN's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. REGN is outperformed by 61.51% of its industry peers.
Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.86 |
ROIC/WACC1.01
WACC8.6%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Current ratio (4.06) which is in line with its industry peers.
A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
REGN's Quick ratio of 3.51 is in line compared to the rest of the industry. REGN outperforms 43.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
The Revenue has been growing slightly by 2.89% in the past year.
Measured over the past years, REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 5.63% on average per year.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.03, which indicates a rather expensive current valuation of REGN.
95.09% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 17.62, the valuation of REGN can be described as rather expensive.
Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 94.91% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.57. REGN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.03 | ||
| Fwd PE | 17.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 94.72% of the companies in the same industry.
95.28% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.98 | ||
| EV/EBITDA | 16.53 |
4.3 Compensation for Growth
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.37
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
REGN has a yearly dividend return of 0.46%, which is pretty low.
REGN's Dividend Yield is rather good when compared to the industry average which is at 1.20. REGN pays more dividend than 98.30% of the companies in the same industry.
With a Dividend Yield of 0.46, REGN pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
5.2 History
REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
NASDAQ:REGN (1/8/2026, 10:11:07 AM)
811.737
-0.53 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.13%
Inst Owner Change0%
Ins Owners1.95%
Ins Owner Change3.32%
Market Cap85.31B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80
Price Target808.25 (-0.43%)
Short Float %2.71%
Short Ratio2.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)4.35%
PT rev (3m)8.5%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)16.02%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)4.37%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.03 | ||
| Fwd PE | 17.62 | ||
| P/S | 5.99 | ||
| P/FCF | 21.98 | ||
| P/OCF | 16.82 | ||
| P/B | 2.76 | ||
| P/tB | 2.88 | ||
| EV/EBITDA | 16.53 |
EPS(TTM)45.01
EY5.54%
EPS(NY)46.06
Fwd EY5.67%
FCF(TTM)36.93
FCFY4.55%
OCF(TTM)48.25
OCFY5.94%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.37
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.86 |
F-Score5
WACC8.6%
ROIC/WACC1.01
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.21%
EBIT Next 3Y6.05%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.